Medicine details

ImageAroxia
NameAroxia
DosageTablet
Generic NameEtoricoxib
Classes Analgesic / Pain Killer
Central Nervous System Agent
NSAID
Diseases Arthritis
Gout
Inflammatory Disease
Pain
CompanyAd-din Pharmaceuticals Ltd.

Drug Package Details

Strength90 mg
Storage Condition
Origin CountryBangladesh
Commercial Pack20
Price per pack160.00
Cost per pack140.80
Package unit10 tabs strip
Price per unit8.00
Cost per unit7.04
Discount0
Coupon
Remarks

Etoricoxib

Etoricoxib  is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, and antipyretic activities. The mechanism of action of Etoricoxib, like that of other NSAIDs, is not completely understood but may be related to prostaglandin synthetase inhibition. 

Etoricoxib is indicated for symptomatic relief of-

  • osteoarthritis
  • rheumatoid arthritis
  • ankylosing spondylitis 
  • Minor pain
  • Dental pain
  • gouty arthritis
  • Osteoarthritis: The recommended dose is 30 mg once daily.  In some patients with insufficient relief from symptoms, the dose may be increased to 60 mg once daily.  In the absence of therapeutic benefit after 4 weeks of treatment with etoricoxib 60 mg, other therapeutic options should be considered. 
  • Primary Dysmenorrhoea: The recommended dose is 120 mg once daily. Etoricoxib should be used only for the acute symptomatic period, limited to a maximum of 8 days treatment. 
  • Dental Pain: The recommended dose is 90 mg once daily. 
  • Acute Gouty Arthritis: The recommended dose is 120 mg once daily.  
  • Psychiatric disorders: insomnia, confusion, hallucinations, depression, restlessness.
  • Immune system disorders: hypersensitivity reactions, anaphylactic/anaphylactoid reactions including shock.
  • Metabolism and nutrition disorders: hyperkalaemia.
  • Nervous system disorders: dysgeusia, somnolence.
  • Cardiac disorders: congestive heart failure, palpitations, angina, arrhythmia.
  • Respiratory, thoracic and mediastinal disorders: bronchospasm, dyspnoea. 
  • Gastrointestinal disorders: abdominal pain, melaena, oral ulcers, peptic ulcers including perforation and bleeding (mainly in elderly patients).
  • Skin and subcutaneous tissue disorders: angioedema, rash, pruritus, erythema, Stevens Johnson syndrome, toxic epidermal necrolysis, urticaria, fixed drug eruption.
  • Renal and urinary disorders: renal insufficiency, including renal failure 
  • Hepatobiliary disorders: hepatitis, jaundice, hepatic failure. Blood and lymphatic system disorders: thrombocytopenia. 

Cardiovascular effects

Clinical trials suggest that the selective COX-2 inhibitor class of drugs may be associated with an increased risk of serious thrombotic events (especially MI and stroke), relative to placebo and some NSAIDs.  Long term safety data beyond one year are not currently available for etoricoxib compared to placebo or NSAIDs other than diclofenac.

  • COX-2 selective inhibitors are not a substitute for aspirin for cardiovascular prophylaxis because of their lack of effect on platelets.  Because etoricoxib, a member of this class, does not inhibit platelet aggregation, antiplatelet therapies should not be discontinued.  
  • In rare cases, patients using etoricoxib may develop peptic ulcers or experience gastrointestinal bleeding.
  • Patients in their advanced years should be closely monitored.
  • Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury.
  • As with other drugs known to inhibit prostaglandin synthesis, fluid retention, oedema and hypertension have been observed in patients taking etoricoxib. 

Contraindication

  • Contraindicated in patients who have shown hypersensitivity to any component of this product.
  • Etoricoxib should not be given to patients who have experienced asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs, such as-

 

Contraindicated in-

  • congestive heart failure
  • hypertension
  • established ischaemic heart disease, peripheral arterial disease and/or cerebrovascular disease (including patients who have recently undergone coronary artery bypass graft surgery or angioplasty). 
  • severe hepatic dysfunction 
  • active peptic ulceration or gastrointestinal (GI) bleeding
  • estimated creatinine clearance < 30 mL/min